Very susceptible to pharmacologic glutathione deprivation. Cancer Res 2010; 70: 9505?514. 38. Locy ML, Rogers
Extremely susceptible to pharmacologic glutathione deprivation. Cancer Res 2010; 70: 9505?514. 38. Locy ML, Rogers LK, Prigge JR, Schmidt EE, Arner ES, Tipple TE. Thioredoxin reductase inhibition elicits Nrf2-mediated responses…